Filing Flows › Connect Biopharma Holdings (CNTB) › Stock forecast & fair value
Connect Biopharma Holdings (CNTB) stock forecast and price target
Connect Biopharma Holdings (CNTB) trades at $0.73. 7 analysts' median price target is $6.00 (+723%), from $4.00 to $9.00.
Connect Biopharma Holdings' latest quarter
Connect Biopharma Holdings, Q2 2026: revenue $2.8M (58× year over year), operating margin -636.0%, net loss $17.3M, operating cash flow −$15.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CNTB stock?
The median of 7 analysts' 12-month targets is $6.00, +723% from $0.73; the range is $4.00 to $9.00. The average rating is strong buy.
Does Connect Biopharma Holdings usually beat earnings estimates?
It beat the consensus EPS estimate in 67% of the quarters on record.
Is CNTB stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.